Fungal Foot Infections Drug Development Pipeline Review, 2018

Home/Fungal Foot Infections Drug Development Pipeline Review, 2018

Fungal Foot Infections Drug Development Pipeline Review, 2018

Pharmaceutical Manufacturing, Pharmacy, Drug Pipeline, Pharma & Healthcare

Publication ID:

GBI0318002

Publication Date:

March 22, 2018

Pages:

Publisher:

GBI Research

Region:

Global

$3,995.00

Need Custom Market Research Solution?

Want to commission a custom market research to suit your needs? We are here to help. Let us know.

Printer version

Send by email

PDF version

Tabs

Description

Fungal Foot Infections Drug Development Pipeline Review, 2018

Summary

This report provides an overview of the fungal foot infection pipeline landscape. It provides comprehensive information on the therapeutics under development for onychomycosis (Tinea unguium) and athlete’s foot (Tinea pedis), and key players active within these indications.

Both of these indications are fungal infections primarily affecting the feet. Onychomycosis affects the nails, whereas athlete’s foot affects the skin under the feet and between the toes. Common symptoms include discomfort, itchiness, and - in the case of onychomycosis - discoloured and disfigured nails. Combined, these infections affect around 25% of the adult population.

There is considerable overlap in both the development of pipeline products and existing marketed products between the two indications, which reflects similarities in the underlying pathophysiology. There are a total of 25 products in development for both indications, by 24 companies.

Scope

- Which companies are the most active within each pipeline?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared with pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Contents

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 Fungal Foot Infections Report Coverage 7
2.2 Onychomycosis (Tinea Unguium) - Overview 7
2.3 Tinea pedis (Athlete Foot) - Overview 7
3 Therapeutics Development 8
3.1 Onychomycosis (Tinea Unguium) 8
3.2 Tinea pedis (Athlete Foot) 12
4 Therapeutics Assessment 15
4.1 Onychomycosis (Tinea Unguium) 15
4.2 Tinea pedis (Athlete Foot) 21
5 Companies Involved in Therapeutics Development 26
5.1 Onychomycosis (Tinea Unguium) 26
5.2 Tinea pedis (Athlete Foot) 32
6 Dormant Projects 36
6.1 Onychomycosis (Tinea Unguium) 36
6.2 Tinea pedis (Athlete Foot) 38
7 Discontinued Products 39
7.1 Onychomycosis (Tinea Unguium) 39
8 Product Development Milestones 40
8.1 Onychomycosis (Tinea Unguium) 40
8.2 Tinea pedis (Athlete Foot) 50
9 Appendix 57
9.1 Methodology 57
9.2 Coverage 57
9.3 Secondary Research 57
9.4 Primary Research 57
9.5 Expert Panel Validation 57
9.6 Contact Us 58
9.7 Disclaimer 58

List of Tables
1.1 List of Tables
Table 1: Number of Products under Development for Onychomycosis (Tinea Unguium) 8
Table 2: Number of Products under Development by Companies, Onychomycosis (Tinea Unguium) 10
Table 3: Products under Development by Companies, Onychomycosis (Tinea Unguium) 11
Table 4: Number of Products under Development for Tinea pedis (Athlete Foot) 12
Table 5: Number of Products under Development by Companies, Tinea pedis (Athlete Foot) 13
Table 6: Products under Development by Companies, Tinea pedis (Athlete Foot) 14
Table 7: Number of Products by Stage and Target, Onychomycosis (Tinea Unguium) 16
Table 8: Number of Products by Stage and Mechanism of Action, Onychomycosis (Tinea Unguium) 17
Table 9: Number of Products by Stage and Route of Administration, Onychomycosis (Tinea Unguium) 19
Table 10: Number of Products by Stage and Molecule Type, Onychomycosis (Tinea Unguium) 20
Table 11: Number of Products by Stage and Target, Tinea pedis (Athlete Foot) 22
Table 12: Number of Products by Stage and Mechanism of Action, Tinea pedis (Athlete Foot) 23
Table 13: Number of Products by Stage and Route of Administration, Tinea pedis (Athlete Foot) 25
Table 14: Number of Products by Stage and Molecule Type, Tinea pedis (Athlete Foot) 25
Table 15: Onychomycosis (Tinea Unguium) - Pipeline by Almirall SA 26
Table 16: Onychomycosis (Tinea Unguium) - Pipeline by Blueberry Therapeutics Ltd 27
Table 17: Onychomycosis (Tinea Unguium) - Pipeline by Dermala Inc 27
Table 18: Onychomycosis (Tinea Unguium) - Pipeline by Eisai Co Ltd 27
Table 19: Onychomycosis (Tinea Unguium) - Pipeline by Helix BioMedix Inc 28
Table 20: Onychomycosis (Tinea Unguium) - Pipeline by Hexima Ltd 28
Table 21: Onychomycosis (Tinea Unguium) - Pipeline by Kaken Pharmaceutical Co Ltd 29
Table 22: Onychomycosis (Tinea Unguium) - Pipeline by Meiji Seika Pharma Co Ltd 29
Table 23: Onychomycosis (Tinea Unguium) - Pipeline by Moberg Pharma AB 30
Table 24: Onychomycosis (Tinea Unguium) - Pipeline by NAL Pharmaceuticals Ltd 30
Table 25: Onychomycosis (Tinea Unguium) - Pipeline by Novabiotics Ltd 31
Table 26: Onychomycosis (Tinea Unguium) - Pipeline by Novan Inc 31
Table 27: Onychomycosis (Tinea Unguium) - Pipeline by Viamet Pharmaceuticals Inc 32
Table 28: Tinea pedis (Athlete Foot) - Pipeline by Astellas Pharma Inc 32
Table 29: Tinea pedis (Athlete Foot) - Pipeline by Biolab Farmaceutica Ltda 33
Table 30: Tinea pedis (Athlete Foot) - Pipeline by Blueberry Therapeutics Ltd 33
Table 31: Tinea pedis (Athlete Foot) - Pipeline by Broda Tech LLC 34
Table 32: Tinea pedis (Athlete Foot) - Pipeline by Novan Inc 34
Table 33: Tinea pedis (Athlete Foot) - Pipeline by Novoteris LLC 35
Table 34: Tinea pedis (Athlete Foot) - Pipeline by Sanotize Research And Development Corp 35
Table 35: Tinea pedis (Athlete Foot) - Pipeline by Viamet Pharmaceuticals Inc 35
Table 36: Onychomycosis (Tinea Unguium) - Dormant Projects 36
Table 37: Tinea pedis (Athlete Foot) - Dormant Projects 38
Table 38: Onychomycosis (Tinea Unguium) - Discontinued Products 39

List of Figures
1.2 List of Figures
Figure 1: Number of Products under Development for Onychomycosis (Tinea Unguium) 8
Figure 2: Number of Products under Development by Companies, Onychomycosis (Tinea Unguium) 9
Figure 3: Number of Products under Development for Tinea pedis (Athlete Foot) 12
Figure 4: Number of Products under Development by Companies, Tinea pedis (Athlete Foot) 13
Figure 5: Number of Products by Targets, Onychomycosis (Tinea Unguium) 15
Figure 6: Number of Products by Stage and Targets, Onychomycosis (Tinea Unguium) 15
Figure 7: Number of Products by Mechanism of Actions, Onychomycosis (Tinea Unguium) 16
Figure 8: Number of Products by Stage and Mechanism of Actions, Onychomycosis (Tinea Unguium) 17
Figure 9: Number of Products by Routes of Administration, Onychomycosis (Tinea Unguium) 18
Figure 10: Number of Products by Stage and Routes of Administration, Onychomycosis (Tinea Unguium) 18
Figure 11: Number of Products by Molecule Types, Onychomycosis (Tinea Unguium) 19
Figure 12: Number of Products by Stage and Molecule Types, Onychomycosis (Tinea Unguium) 20
Figure 13: Number of Products by Targets, Tinea pedis (Athlete Foot) 21
Figure 14: Number of Products by Stage and Targets, Tinea pedis (Athlete Foot) 21
Figure 15: Number of Products by Mechanism of Actions, Tinea pedis (Athlete Foot) 22
Figure 16: Number of Products by Stage and Mechanism of Actions, Tinea pedis (Athlete Foot) 23
Figure 17: Number of Products by Routes of Administration, Tinea pedis (Athlete Foot) 24
Figure 18: Number of Products by Stage and Routes of Administration, Tinea pedis (Athlete Foot) 24
Figure 19: Number of Products by Stage and Molecule Types, Tinea pedis (Athlete Foot) 25

Companies Covered

Almirall SA
Astellas Pharma Inc
Biolab Farmaceutica Ltda
Blueberry Therapeutics Ltd
Broda Tech LLC
Dermala Inc
Eisai Co Ltd
Helix BioMedix Inc
Hexima Ltd
Kaken Pharmaceutical Co Ltd
Meiji Seika Pharma Co Ltd
Moberg Pharma AB
NAL Pharmaceuticals Ltd
Novabiotics Ltd
Novan Inc
Novoteris LLC
Onychomycosis (Tinea Unguium)
Sanotize Research And Development Corp
Tinea pedis (Athlete Foot)
Viamet Pharmaceuticals Inc

Report License Types

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Report Enquiry

Do you need more information about this report before making a purchase decision or wish to customize this report to suite your requirements?

If yes, then please use the form given below and we will get in touch with you immediately.

Kindly use your official email address and contact number to ensure speedy response.

Name *

Email *

Company

Contact Number *

Report Title *

Your Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Drag or click the correct shape to the grey "drop area".